- Home
- ITCI vs CPB Comparison
ITCI vs CPB Comparison
Compare ITCI & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITCI
- CPB
- Stock Information
- Founded
- ITCI 2002
- CPB 1869
- Country
- ITCI United States
- CPB United States
- Employees
- ITCI N/A
- CPB N/A
- Industry
- ITCI Biotechnology: Pharmaceutical Preparations
- CPB Packaged Foods
- Sector
- ITCI Health Care
- CPB Consumer Staples
- Exchange
- ITCI Nasdaq
- CPB Nasdaq
- Market Cap
- ITCI 13.5B
- CPB 11.9B
- IPO Year
- ITCI N/A
- CPB N/A
- Fundamental
- Price
- ITCI $131.36
- CPB $38.47
- Analyst Decision
- ITCI Buy
- CPB Hold
- Analyst Count
- ITCI 13
- CPB 16
- Target Price
- ITCI $106.58
- CPB $45.60
- AVG Volume (30 Days)
- ITCI 2.2M
- CPB 3.8M
- Earning Date
- ITCI 05-06-2025
- CPB 03-05-2025
- Dividend Yield
- ITCI N/A
- CPB 4.05%
- EPS Growth
- ITCI N/A
- CPB N/A
- EPS
- ITCI N/A
- CPB 1.73
- Revenue
- ITCI $680,852,000.00
- CPB $10,119,000,000.00
- Revenue This Year
- ITCI $40.64
- CPB $9.81
- Revenue Next Year
- ITCI $58.53
- CPB N/A
- P/E Ratio
- ITCI N/A
- CPB $22.22
- Revenue Growth
- ITCI 46.62
- CPB 9.15
- 52 Week Low
- ITCI $63.30
- CPB $36.92
- 52 Week High
- ITCI $131.37
- CPB $52.81
- Technical
- Relative Strength Index (RSI)
- ITCI 85.33
- CPB 43.76
- Support Level
- ITCI $131.19
- CPB $38.07
- Resistance Level
- ITCI $131.37
- CPB $43.85
- Average True Range (ATR)
- ITCI 0.26
- CPB 1.60
- MACD
- ITCI -0.55
- CPB -0.15
- Stochastic Oscillator
- ITCI 99.70
- CPB 6.92
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
About CPB Campbell Soup Company
Over the past 150-plus years, Campbell has evolved into a leading packaged food manufacturer in North America, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2024, snacks accounted for nearly half of its revenue, followed by soup (28%), other simple meals (17%), and beverages (7%). Outside its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and recently acquired Rao's (a deal that closed in March 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.